{"id":270723,"date":"2026-01-06T18:19:13","date_gmt":"2026-01-06T18:19:13","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/270723\/"},"modified":"2026-01-06T18:19:13","modified_gmt":"2026-01-06T18:19:13","slug":"variant-bio-launches-ai-powered-platform-for-drug-discovery-using-genetic-data","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/270723\/","title":{"rendered":"Variant Bio launches AI-powered platform for drug discovery using genetic data"},"content":{"rendered":"\n<p class=\"yf-7hmkaz\">Jan 6 (Reuters) &#8211; Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that \u200buses <a href=\"https:\/\/tech.yahoo.com\/ai\/\" data-ylk=\"slk:artificial intelligence;elm:context_link;itc:0;sec:content-canvas\" class=\"link \" rel=\"nofollow noopener\" target=\"_blank\">artificial intelligence<\/a> on genetic data to discover new \u200cdrug candidates to send into human trials.<\/p>\n<p class=\"yf-7hmkaz\">Drug developers are increasing adoption of \u200cAI for discovery and safety trials to get faster and cheaper results, in line with a push by the U.S. Food and Drug Administration to reduce animal testing in the near future.<\/p>\n<p class=\"yf-7hmkaz\">Variant&#8217;s \u2060Inference platform uses agentic \u200cAI &#8211; autonomous AI agents that work with minimal human intervention &#8211; to discover drugs by analyzing proprietary \u200dand public human genomic data from global studies, along with other large-scale biological datasets.<\/p>\n<p class=\"yf-7hmkaz\">Separately, the AI discovery company also announced a multi-year research \u200bcollaboration and license agreement with Boehringer Ingelheim to discover drugs \u200cfor kidney disease using its Inference platform.<\/p>\n<p class=\"yf-7hmkaz\">Under the agreement, Variant Bio will receive an upfront payment and will be eligible for potential license and milestone payments totaling over $120 million.<\/p>\n<p class=\"yf-7hmkaz\">Variant Bio said its Inference platform is now available to research partners and \u2060that it has collaborations with several \u200bpharmaceutical companies in deals totaling more \u200bthan $200 million.<\/p>\n<p class=\"yf-7hmkaz\">Drugmaker Eli Lilly last year also launched an AI and machine learning platform called TuneLab to \u200dprovide biotech companies \u2060access to drug discovery models trained on years of its research data.<\/p>\n<p class=\"yf-7hmkaz\">Several other drugmakers have also announced collaborations in \u2060an effort to share proprietary data for training AI models to assist \u200cdrug discovery and development.<\/p>\n<p class=\"yf-7hmkaz\">(Reporting by Sneha S K in \u200cBengaluru; Editing by Leroy Leo)<\/p>\n","protected":false},"excerpt":{"rendered":"Jan 6 (Reuters) &#8211; Variant Bio, a private biotech firm, said on Tuesday it has launched a platform&hellip;\n","protected":false},"author":2,"featured_media":270724,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[261],"tags":[291,289,290,135267,4948,18,79828,138030,19,17,138029,82,93930,138031],"class_list":{"0":"post-270723","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-artificial-intelligence","8":"tag-ai","9":"tag-artificial-intelligence","10":"tag-artificialintelligence","11":"tag-boehringer-ingelheim","12":"tag-discovery","13":"tag-eire","14":"tag-genetic-data","15":"tag-human-trials","16":"tag-ie","17":"tag-ireland","18":"tag-proprietary-data","19":"tag-technology","20":"tag-variant","21":"tag-variant-bio"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115849537975726209","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/270723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=270723"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/270723\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/270724"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=270723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=270723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=270723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}